Atazanavir Sulfate | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Atazanavir Sulfate
US Patents

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Atazanavir Sulfate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 25 USDMF, 7 CEP/COS, 15 EU WC, 2 KDMF, 18 NDC API, 20 Listed Suppliers, $ API Reference Price

41 API Suppliers
25 USDMF
7 CEP/COS
15 EU WC
2 KDMF
18 NDC API
20 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

67 FDF Dossiers, 42 FDA Orange Book, 8 Europe, 11 Canada, 6 Listed Dossiers

67 FDF Dossiers
42 FDA Orange Book
8 Europe
11 Canada
6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

TABLET;ORAL - EQ 300MG BASE;150MG
CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - EQ 200MG BASE
CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 8 DKSH, 4 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 17 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 1 Valens Pharmachem, 4 Vasa Pharmachem

1 Rochem International Inc
1 SPI Pharma
8 DKSH
4 Faran Shimi Pharmaceutical
5 Gangwal Healthcare
3 Nanjing Well Pharmaceutical
1 Pfanstiehl
4 ACG Worldwide
1 Actylis
6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
8 BASF
6 DFE Pharma
1 Finar
6 Gangwal Chemicals
1 Ideal Cures Pvt Ltd
2 Ingredion Pharma Solutions
17 Kerry
3 Lonza Capsugel
12 Microlex e.U
2 Pharmatrans-Sanaq
4 Pluviaendo
4 Prachin Chemical
1 Qualicaps
14 Roquette
3 Seppic
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
11 Sigachi Industries
1 Valens Pharmachem
4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

43 Fillers, Diluents & Binders, 22 Disintegrants & Superdisintegrants, 20 Thickeners and Stabilizers, 16 Lubricants & Glidants, 15 Granulation, 14 Direct Compression, 13 Coating Systems & Additives, 8 Film Formers & Plasticizers, 8 Empty Capsules, 7 Topical, 7 Emulsifying Agents, 7 Co-Processed Excipients, 7 Taste Masking, 4 Controlled & Modified Release, 4 Parenteral, 4 Solubilizers, 3 Coloring Agents, 3 Chewable & Orodispersible Aids, 3 Surfactant & Foaming Agents, 2 Rheology Modifiers, 1 API Stability Enhancers

43 Fillers, Diluents & Binders
22 Disintegrants & Superdisintegrants
20 Thickeners and Stabilizers
16 Lubricants & Glidants
15 Granulation
14 Direct Compression
13 Coating Systems & Additives
8 Film Formers & Plasticizers
8 Empty Capsules
7 Topical
7 Emulsifying Agents
7 Co-Processed Excipients
7 Taste Masking
4 Controlled & Modified Release
4 Parenteral
4 Solubilizers
3 Coloring Agents
3 Chewable & Orodispersible Aids
3 Surfactant & Foaming Agents
2 Rheology Modifiers
1 API Stability Enhancers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 10 News #PharmaBuzz

1 Data Compilation #PharmaFlow
10 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 5 Annual Reports

2 US Medicaid Prescriptions
5 Annual Reports

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 8 Health Canada Patents

2 US Patents
8 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 1 Others

2 USP
1 Others

$ API Ref.Price (USD/KG) : 881 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

2 All

01 2BRISTOL

filter Patent Number Reset all filters

2 All

01 18148374

02 110039718

filter API Patent Reset all filters

2 All

01 1Y

02 1Blank

filter FDF Patent Reset all filters

2 All

01 2Y

filter Expiration Date Reset all filters

2 All

01 12029-09-03

02 12032-10-06

Product Main Page

01

BRISTOL

ATAZANAVIR SULFATE; COBICISTAT

Immuno-Oncology 360

Not Confirmed

BRISTOL

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-03

ATAZANAVIR SULFATE; COBICISTAT

US Patent Number : 8148374

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206353

Patent Use Code : U-1279

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2029-09-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

BRISTOL

ATAZANAVIR SULFATE; COBICISTAT

Immuno-Oncology 360

Not Confirmed

BRISTOL

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-10-06

ATAZANAVIR SULFATE; COBICISTAT

US Patent Number : 10039718

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206353

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-10-06

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!